XML 37 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flow from operating activities:    
Net income $ 1,748.1 $ 3,702.9
Adjustments to reconcile net income to net cash flow from operating activities:    
Depreciation and amortization 353.0 347.5
Impairment of intangible assets 629.3 19.3
Acquired in-process research and development 18.0 75.0
Share-based compensation 179.8 149.3
Contingent consideration (49.1) (23.5)
Deferred income taxes (750.1) 211.9
(Gain) loss on strategic investments 710.5 41.8
(Gain) loss on equity method investment (17.2) 14.7
Other 201.0 110.1
Changes in operating assets and liabilities, net:    
Accounts receivable 157.8 (135.7)
Due from anti-CD20 therapeutic programs 13.5 63.0
Inventory (322.6) (270.6)
Accrued expense and other current liabilities (243.3) 372.9
Income tax assets and liabilities 260.5 15.3
Other changes in operating assets and liabilities, net (87.6) (97.0)
Net cash flow provided by operating activities 2,801.6 4,596.9
Cash flows from investing activities:    
Purchases of property, plant and equipment (206.5) (338.8)
Proceeds from sales and maturities of marketable securities 2,028.1 5,240.7
Purchases of marketable securities (2,372.6) (4,649.1)
Proceeds from divestiture of Hillerød, Denmark manufacturing operations 28.1 0.0
Acquired in-process research and development (18.0) (75.0)
Acquisitions of intangible assets (1.9) (37.0)
Proceeds from sales of strategic investments 91.2 0.5
Other 0.6 (18.0)
Net cash flow used in investing activities (451.0) (442.2)
Cash flows from financing activities:    
Purchases of treasury stock (1,800.0) (6,279.1)
Payments related to issuance of stock for share-based compensation arrangements, net (8.3) (11.8)
Repayment of borrowings and premiums paid on debt exchange (170.0) 0.0
Proceeds from borrowings 0.0 2,967.3
Repayment of borrowings 0.0 (1,500.0)
Cash proceeds from settlement of swap 0.0 0.0
Net distribution to noncontrolling interest (94.8) (70.9)
Other (22.9) 22.9
Net cash flow used in financing activities (2,096.0) (4,871.6)
Net increase (decrease) in cash and cash equivalents 254.6 (716.9)
Effect of exchange rate changes on cash and cash equivalents (44.0) 28.0
Cash and cash equivalents, beginning of the period 1,331.2 2,913.7
Cash and cash equivalents, end of the period 1,541.8 2,224.8
Sangamo    
Cash flows from investing activities:    
Payments subsidiary and affiliates stock 0.0 (141.8)
Denali Therapeutics    
Cash flows from investing activities:    
Payments subsidiary and affiliates stock $ 0.0 $ (423.7)